GangaGen Secures additional US$7.9 Million from CARB-X for Pre-clinical Development of Novel Klebicins Targeting Nosocomial Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae
by BANGALORE, INDIA / SINGAPORE – Media OutReach Newswire – 23 December 2024 – GangaGen announced today that it has secured the third instalment of its …